Although diesel airborne particulate matter (PM2.5) has been known to play a role in many human diseases, there is no direct evidence that therapeutic drugs or proteins can diminish PM2.5‐induced diseases. Nevertheless, studies examining the negative control mechanisms of PM2.5‐induced diseases are critical to develop novel therapeutic medications. In this study, the consensus PDZ peptide of ZO‐1 inhibited PM2.5‐induced inflammatory cell infiltration, pro‐inflammatory cytokine gene expression, and TEER in bronchoalveolar lavage (BAL) fluid and AM cells. Our data indicated that the PDZ domain in ZO‐1 is critical for regulation of the PM2.5‐induced inflammatory microenvironment. Therefore, the PDZ peptide may be a potential therapeutic candidate during PM‐induced respiratory diseases.

中文翻译：

---

ZO-1的PDZ基序肽下调柴油机颗粒物诱导的气道炎症。

尽管已知柴油中的空气中颗粒物（PM2.5）在许多人类疾病中起作用，但尚无直接证据表明治疗药物或蛋白质可以减轻PM2.5引起的疾病。尽管如此，研究PM2.5诱发疾病的阴性控制机制的研究对于开发新型治疗药物至关重要。在这项研究中，ZO-1的共有PDZ肽抑制了支气管肺泡灌洗（BAL）液和AM细胞中PM2.5诱导的炎症细胞浸润，促炎细胞因子基因表达和TEER。我们的数据表明，ZO-1中的PDZ域对于调节PM2.5诱导的炎症微环境至关重要。因此，PDZ肽可能是PM诱发的呼吸系统疾病的潜在治疗候选物。